This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
by Zacks Equity Research
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
by Zacks Equity Research
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
by Zacks Equity Research
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
by Zacks Equity Research
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
by Zacks Equity Research
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
by Zacks Equity Research
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
by Zacks Equity Research
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
by Zacks Equity Research
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
by Zacks Equity Research
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
by Zacks Equity Research
PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
by Zacks Equity Research
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25% and 5.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
by Zacks Equity Research
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
by Zacks Equity Research
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of -21.43% and 27.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Perrigo to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.